Torrent Pharmaceuticals Ltd. (TORNTPHARM) fundamentals
Torrent Pharmaceuticals Ltd. is a listed company in Pharmaceuticals & Biotechnology, part of the Healthcare sector, listed on the NSE as TORNTPHARM (ISIN INE685A01028). This page carries its reported financials, balance sheet, cash flow, shareholding pattern and valuation ratios.
What Torrent Pharmaceuticals Ltd. does
Torrent Pharmaceuticals Limited is an India-based pharmaceutical company. The Company is engaged in research, development, manufacturing, marketing and distribution of branded and generic pharmaceutical formulations in India and internationally. The Company is focused on various therapeutic segments, such as cardiovascular (CV), central nervous system (CNS), gastrointestinal (GI), vitamins minerals nutrients (VMN), anti-diabetes (AD), pain management, gynecology, and dermatology. Its pediatric product brands include Tedibar, Atogla, Spoo and B4 Nappi. Its Anti-diabetic products include Gliclazide 80 mg, Tablets, Gliclazide 30 mg, Tablets, Glimepiride 1, 2, 3, 4 mg, Tablets, and others. Its dermatologic therapy products include Macrotor, Ahaglow S Facewash, Fungicide Lotion, Hairjoy 2%, New Dewsoft Cream, Lookbrite 20GMS, Cortaz NC, Dermanex, and others. Its manufacturing facilities are located in the states of Gujarat, Himachal Pradesh, Madhya Pradesh, Andhra Pradesh and Sikkim.
Valuation and market data
| Last close | ₹4625.00 |
|---|---|
| Market capitalisation | ₹1.55 lakh crore |
| Enterprise value | ₹1.72 lakh crore |
| P/E (TTM) | 72.36 |
| Price to book | 8.80 |
| Price to sales (TTM) | 6.08 |
| Book value per share | ₹525.69 |
| Dividend yield | 82.16% |
| Sector | Healthcare |
| Industry | Pharmaceuticals & Biotechnology |
| Listed since | Mon Nov 25 |
Annual results
| Period | Revenue | Profit before tax | Net profit | EPS |
|---|---|---|---|---|
| Mar 2026 | ₹10,730 crore | ₹2,897 crore | ₹2,192 crore | 64.75 |
| Mar 2025 | ₹9,714 crore | ₹2,610 crore | ₹1,888 crore | 55.79 |
| Mar 2024 | ₹8,624 crore | ₹1,917 crore | ₹1,357 crore | 40.10 |
| Mar 2023 | ₹7,777 crore | ₹1,577 crore | ₹1,051 crore | 31.07 |
Figures are as reported (standalone), in ₹ crore.
Shareholding pattern
As of Sep 2026:
| Promoters | 60.8% |
|---|---|
| Foreign institutions (FII) | 17.2% |
| Mutual funds | 8.8% |
| Other domestic institutions | 4.6% |
| Retail and others | 8.5% |
More on BreakPoint
FundaX company research covers every listed company with reported financials. BreakPoint Pro adds the BreakPoint iQ score, the screener and the multibagger board.
Data is sourced from exchange filings and vendor feeds and is for research, not investment advice. Figures can be restated by the company after publication.